Literature DB >> 16960851

Seeing the NICE side of cost-effectiveness analysis: a qualitative investigation of the use of CEA in NICE technology appraisals.

Stirling Bryan1, Iestyn Williams, Shirley McIver.   

Abstract

Resource scarcity is the raison d'être for the discipline of economics. Thus, the primary purpose of economic analysis is to help decision-makers when addressing problems arising due to the scarcity problem. The research reported here was concerned with how cost-effectiveness information is used by the National Institute for Health & Clinical Excellence (NICE) in national technology coverage decisions in the UK, and how its impact might be increased. The research followed a qualitative case study methodology with semi-structured interviews, supported by observation and analysis of secondary sources. Our research highlights that the technology appraisal function of NICE represents an important progression for the UK health economics community: new cost-effectiveness work is commissioned for each technology and that work directly informs national health policy. However, accountability in policy decisions necessitates that the information upon which decisions are based (including cost-effectiveness analysis, CEA) is accessible. This was found to be a serious problem and represents one of the main ongoing challenges. Other issues highlighted include perceived weaknesses in analysis methods and the poor alignment between the health maximisation objectives assumed in economic analyses and the range of other objectives facing decision-makers in reality. Copyright (c) 2006 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  2007        PMID: 16960851     DOI: 10.1002/hec.1133

Source DB:  PubMed          Journal:  Health Econ        ISSN: 1057-9230            Impact factor:   3.046


  17 in total

Review 1.  Economic evaluation and decision making in the UK.

Authors:  Martin J Buxton
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

2.  A stated preference binary choice experiment to explore NICE decision making.

Authors:  Paul Tappenden; John Brazier; Julie Ratcliffe; James Chilcott
Journal:  Pharmacoeconomics       Date:  2007       Impact factor: 4.981

3.  Public funding of pharmaceuticals in The Netherlands: investigating the effect of evidence, process and context on CVZ decision-making.

Authors:  Karin H Cerri; Martin Knapp; Jose-Luis Fernandez
Journal:  Eur J Health Econ       Date:  2013-07-18

4.  Requisite models for strategic commissioning: the example of type 1 diabetes.

Authors:  Mara Airoldi; Gwyn Bevan; Alec Morton; Mónica Oliveira; Jenifer Smith
Journal:  Health Care Manag Sci       Date:  2008-06

5.  Use of cost-effectiveness data in priority setting decisions: experiences from the national guidelines for heart diseases in Sweden.

Authors:  Nathalie Eckard; Magnus Janzon; Lars-Åke Levin
Journal:  Int J Health Policy Manag       Date:  2014-10-27

6.  Field testing of a multicriteria decision analysis (MCDA) framework for coverage of a screening test for cervical cancer in South Africa.

Authors:  Jacqui Miot; Monika Wagner; Hanane Khoury; Donna Rindress; Mireille M Goetghebeur
Journal:  Cost Eff Resour Alloc       Date:  2012-02-29

Review 7.  NICE cost-effectiveness appraisal of cholinesterase inhibitors: was the right question posed? Were the best tools used?

Authors:  Denis Getsios; Kristen Migliaccio-Walle; Jaime J Caro
Journal:  Pharmacoeconomics       Date:  2007       Impact factor: 4.981

Review 8.  Developing a reference protocol for structured expert elicitation in health-care decision-making: a mixed-methods study.

Authors:  Laura Bojke; Marta Soares; Karl Claxton; Abigail Colson; Aimée Fox; Christopher Jackson; Dina Jankovic; Alec Morton; Linda Sharples; Andrea Taylor
Journal:  Health Technol Assess       Date:  2021-06       Impact factor: 4.014

9.  Cost-effectiveness of pioglitazone in type 2 diabetes patients with a history of macrovascular disease: a German perspective.

Authors:  Werner A Scherbaum; Gordon Goodall; Katrina M Erny-Albrecht; Massimo Massi-Benedetti; Erland Erdmann; William J Valentine
Journal:  Cost Eff Resour Alloc       Date:  2009-05-05

10.  Decision-making in healthcare: a practical application of partial least square path modelling to coverage of newborn screening programmes.

Authors:  Katharina E Fischer
Journal:  BMC Med Inform Decis Mak       Date:  2012-08-02       Impact factor: 2.796

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.